Nikolai Makukhin

Nikolai Makukhin

Auto-generated profile, based on publicly available information

Nikolai Makukhin

Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre, Dundee DD1 5EH, U.K.

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Science Advances
Verified
Journal Article
Open access
CCCharlotte Crowe
Charlotte Crowe
MNMark A. Nakasone
Mark A. Nakasone
SCSarah Chandler
Sarah Chandler
CCConner Craigon
Conner Craigon
GSGajanan Sathe
Gajanan Sathe
ACAlessio Ciulli
Alessio Ciulli
Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4 BD2 toward UBE2R1-ubiquitin, and Lys 456 at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4 BD2 , with cellular degradation and ubiquitinomics confirming the importance of Lys 456 and nearby Lys 368 /Lys 445 , identifying the “ubiquitination zone.” Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4 BD2 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design.

15 October 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
NMNikolai Makukhin
Nikolai Makukhin
ACAlessio Ciulli
Alessio Ciulli
This review summarizes advances over the last decade in the design of phosphotyrosine and its phosphonate-based derivatives, focusing on their synthesis and medicinal chemistry applications.

1 May 2011 in Russian Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
NGN. S. Gulyukina
N. S. Gulyukina
NMN. N. Makukhin
N. N. Makukhin
Irina Petrovna  BeletskayaIrina Petrovna Beletskaya
Irina Petrovna Beletskaya
Known methods of preparation of (1-aminocyclopropyl)phosphonic acids and their derivatives are analyzed.

15 September 2022 in ChemMedChem
Verified
Journal Article
Open access
ACAlessandra Cipriano
Alessandra Cipriano
CMCiro Milite
Ciro Milite
AFAlessandra Feoli
Alessandra Feoli
MVMonica Viviano
Monica Viviano
Giacomo PepeGiacomo Pepe
Giacomo Pepe
GGianluca Sbardella
Gianluca Sbardella
The bromodomain and extra‐terminal (BET) family of proteins includes BRD2, BRD3, BRD4, and the testis‐specific protein, BRDT, each containing two N‐terminal tandem bromodomain (BRD) modules. Potent and selective inhibitors targeting the two bromodomains are required to elucidate their biological role(s), with potential clinical applications. In this study, we designed and synthesized a series of benzimidazole‐6‐sulfonamides starting from the azobenzene compounds MS436 (7 a) and MS611 (7 b) that exhibited preference for the first (BD1) over the second (BD2) BRD of BET family members. The most‐promising compound (9 a) showed good binding potency and improved metabolic stability and selectivity towards BD1 with respect to the parent compounds.

5 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CCCharlotte Crowe
Charlotte Crowe
MNMark A. Nakasone
Mark A. Nakasone
SCSarah Chandler
Sarah Chandler
MTMichael H. Tatham
Michael H. Tatham
NMNikolai Makukhin
Nikolai Makukhin
ACAlessio Ciulli
Alessio Ciulli
Small molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and the potential to tackle previously undrugged targets. Thermodynamically stable and kinetically long-lived degrader-mediated ternary complexes can drive faster, more profound and durable target degradation, however the mechanistic features by which they impact on target ubiquitination remain elusive. Here, we solve cryo-EM structures of the VHL Cullin 2 RING E3 ligase complexed with degrader MZ1, target protein Brd4 BD2 and primed for catalysis with its cognate E2-ubiquitin bound. We find that Brd4 BD2 adopts a favourable orientation towards the E2 active site. In vitro ubiquitination coupled with mass spectrometry illuminates a patch of ubiquitinable lysines on one face of Brd4 BD2 , with Lys456 showing optimal distance and geometry for nucleophilic attack. Our results demonstrate the proficiency of MZ1 in directing the substrate towards catalysis, explains the favourability of Brd4 BD2 for ubiquitination, and reveals the flexibility of the enzyme in capturing sub-optimal lysines. We propose a model for ubiquitinability of degrader-recruited targets that provides a mechanistic blueprint for further rational drug design and optimization. One-Sentence Summary: Structural assembly a PROTAC-mediated complex of whole Cullin RING E3 ligase with bound target and E2-ubiquitin reveals structural and mechanistic insights of specificity for target protein ubiquitination.

3 June 2026 in Biochemical Journal
Verified
Journal Article
Open access
SCSarah F. Chandler
Sarah F. Chandler
MTMichael H. Tatham
Michael H. Tatham
EBEmma Branigan
Emma Branigan
MNMark A. Nakasone
Mark A. Nakasone
NMNikolai Makukhin
Nikolai Makukhin
RHRonald T. Hay
Ronald T. Hay
Almost all cellular processes are influenced by ubiquitination. A large family of enzymes known as E3 ligases provides the specificity for ubiquitination, with the largest class among them, the Really Interesting New Gene (RING) E3s, comprising over 600 members in humans. RING E3s facilitate transfer of ubiquitin (Ub) to substrates by constraining the highly dynamic E2–Ub thioester linkage to be primed for attack from the substrate nucleophile. We have established a workflow that uses an N-maleimido diazirine (NMD) photoactivatable cross-linker attached to ubiquitin that, once stably linked to the active site of an E2, creates an activity-based probe (ABP) to monitor interactions with E3 ligases. Cross-linking mass spectrometry using the NMD-Ub-E2 ABP identified regions of interaction between ubiquitin and a selection of different RING E3s, which not only agreed with existing crystal structures, but was also used to evaluate in silico structural models of complexes yet to be resolved by conventional means. The cross-linking data also provided insight into domains of conformational flexibility which likely adopt multiple configurations in solution and which are challenging to monitor by other methods. NMD-Ub-E2 ABPs offer great potential to explore the ensemble conformations of E2–E3 complexes in solution and have scope for applications beyond the ubiquitin system.